Alnylam Pharmaceuticals (ALNY) Total Liabilities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Total Liabilities data on file, last reported at $4.2 billion in Q2 2026.

• Quarterly Total Liabilities fell 2.57% year-over-year to $4.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.2 billion (down 2.57% YoY) and the FY2025 annual result came in at $4.2 billion, changed 0.1% from the prior year.
• Total Liabilities grew to $4.2 billion in Q2 2026, from $4.1 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $4.6 billion in Q3 2025 to a low of $3.0 billion in Q1 2022.
• A 5-year average of $3.9 billion and a median of $4.0 billion in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 32.63% — and 2026, when it decreased 2.57%.
• Tracing ALNY's Total Liabilities over 5 years: stood at $3.7 billion in 2022, then gained by 9.34% to $4.1 billion in 2023, then rose by 3.02% to $4.2 billion in 2024, then rose by 0.1% to $4.2 billion in 2025, then increased by 0.66% to $4.2 billion in 2026.
• The last three Total Liabilities figures came in at $4.2 billion (Q2 2026), $4.1 billion (Q1 2026), and $4.2 billion (Q4 2025), per Business Quant data.